EIRGENIX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.3 TWD | +1.73% |
|
+2.06% | -6.17% |
EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
94.3
TWD
Average target price
112.5
TWD
Spread / Average Target
+19.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.17% | 885M | |
| +8.54% | 100B | |
| +11.97% | 43.89B | |
| -11.76% | 33.24B | |
| +79.85% | 29.36B | |
| -12.20% | 16.08B | |
| +4.00% | 14.68B | |
| -1.90% | 12.87B | |
| +178.17% | 10.55B | |
| +3.30% | 8.83B |
- Stock Market
- Equities
- 6589 Stock
- News EirGenix Inc.
- EirGenix Unit Gets FDA Nod for Biologic License Application Resubmission for Cancer Drug